Your cart is empty.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Männedorf, Switzerland, January 17, 2012 – The Tecan Group (SIX Swiss Exchange: TECN) today announced an OEM agreement with Waters Corporation (NYSE:WAT). Under the agreement, Tecan will supply instruments for the sample preparation of Waters’ clinical laboratory assays. The instrument is based on Tecan’s flexible and reliable Freedom EVO® liquid handling platform and will be used as a component of the Waters® system in combination with a Waters ACQUITY® TQD liquid chromatograph/mass spectrometer (LC/MS/MS).
Tecan expects to start the commercial supply of instruments within the next six months. Financial details of the agreement were not disclosed.
Waters and ACQUITY are trademarks of Waters Corporation.
Tecan and Freedom EVO are trademarks of the Tecan Group Ltd.
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2010, Tecan generated sales of CHF 371 million (USD 356 million; EUR 269 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN: 1210019).
About Waters Corporation
For over 50 years, Waters Corporation (NYSE:WAT) has created business advantages for laboratorydependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.
With revenue of $1.64 billion in 2010 and 5,400 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.
For further information
Tecan Group |
|
Waters Corporation |
Martin Braendle | Brian J. Murphy | |
Head of Corporate Communications & Investor Relations |
Waters Corporation | |
Tel. +41 (0) 44 922 84 30 | Public Relations | |
Fax +41 (0) 44 922 88 89 | +1 508-482-2614 | |
investor@tecan.com | brian_j_murphy@waters.com | |
www.tecan.com |
Downloads: